Design Therapeutics (DSGN) Accounts Payables (2020 - 2026)

Design Therapeutics (DSGN) has 7 years of Accounts Payables data on file, last reported at $2.3 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables fell 28.43% year-over-year to $2.3 million; the trailing twelve-month figure through Mar 2026 stood at $2.3 million (down 28.43% YoY), and the FY2025 full-year result was $2.3 million, up 5.76% from the prior year.
• Accounts Payables slipped to $2.3 million in Q1 2026, from $2.3 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $3.2 million in Q1 2025 to a low of $1.0 million in Q2 2025.
• A 5-year average of $2.1 million and a median of $2.1 million in 2022 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables slumped 50.0% in 2024 and surged 131.78% in 2025, its largest moves.
• Tracing DSGN's Accounts Payables over 5 years: stood at $3.0 million in 2022, then sank by 35.87% to $1.9 million in 2023, then grew by 12.68% to $2.2 million in 2024, then grew by 5.76% to $2.3 million in 2025, then decreased by 1.56% to $2.3 million in 2026.
• Business Quant data shows DSGN's Accounts Payables at $2.3 million in Q1 2026, $2.3 million in Q4 2025, and $1.9 million in Q3 2025.